跳至主要内容
临床试验/KCT0003539
KCT0003539招募中未知

DEvelopment of Tools for Early diagnosis of operable Cancer with muTation enrichment plasma DNA sequencing and blood tumor marker

Kangbuk Samsung Medical Center0 个研究点目标入组 840 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
840

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational Study

入排标准

年龄范围
20(Year) 至 o Limit(—)
性别
All

入选标准

  • 1. Histologically confirmed malignancy or strongly suspicious malignancy on PET-CT / CT scanning
  • 2. Patients scheduled for curative intended surgery and/or radiotherapy
  • 3. No previous chemotherapy or radiotherapy before curative intended surgery
  • 4. 20 years and older
  • 5. Ability to provide written informed consent for blood sampling
  • 6. Ability to understand the right to withdraw written informed consent without disadvantages

排除标准

  • 1. Previous history of chemotherapy and/or radiotherapy and/or curative intended surgery before study enrollment.
  • 2. Previous history of malignancy within 3 years
  • 3. History of organ transplantation requiring immunosuppressive treatment or peripheral blood stem cell transplantation

研究者

相似试验

Development of tools for early diagnosis of operable... | 临床试验